{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:50:45Z","timestamp":1781923845870,"version":"3.54.5"},"reference-count":13,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and short-term safety of botulinum toxin type A (BTX-A) injection into the inferior oblique muscle for treating inferior oblique overaction (IOOA) in a pediatric cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study at King Khaled Eye Specialist Hospital &amp; Research Center, Riyadh, Saudi Arabia, including children aged 2\u201315 years with IOOA treated with BTX-A injections between June 2022 and September 2024. Data on demographics, baseline IOOA grade, associated strabismus, and postoperative complications were collected. All included eyes had a baseline IOOA grade of 2+ to 4+ and underwent a 5.00 units injection of BTX-A (Botox, Allergan Inc., Irvine, California, USA) to the inferior oblique muscle in a trans-conjunctival technique. The primary outcome was IOOA resolution, defined as postoperative IOOA grade of 0 or +1 at three months following the injection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-three patients (42 eyes) were analyzed. Median age was 6 years (IQR: 5\u20138), with 56% were female. Bilateral IOOA was present in 83% of included patients, esotropia in 91%, and exotropia in 9%. Three months after injection, 54% of eyes achieved complete or near complete IOOA resolution, and 76% improved by at least one grade. Exotropia decreased from 36% at two weeks to 5% at three months (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001), while ptosis declined from 29% to 2% (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>BTX-A injection into the IO muscle is effective and safe for primary IOOA, with significant short-term improvement and minimal transient complications. The long-term sustainability of the IOOA improvement post BTX-A injection is unknown.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11206721251414695","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:27:27Z","timestamp":1767986847000},"page":"1048-1053","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of botulinum toxin injection in treating primary inferior oblique overaction: A retrospective cohort study"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7798-3517","authenticated-orcid":false,"given":"Ghadah","family":"AlQahtani","sequence":"first","affiliation":[{"name":"King Khaled Eye Specialist Hospital & Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4320-448X","authenticated-orcid":false,"given":"Gorka","family":"Sesma","sequence":"additional","affiliation":[{"name":"King Khaled Eye Specialist Hospital & Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh","family":"AlMesfer","sequence":"additional","affiliation":[{"name":"King Khaled Eye Specialist Hospital & Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3028-1016","authenticated-orcid":false,"given":"Fawzia","family":"Alhaimi","sequence":"additional","affiliation":[{"name":"King Khaled Eye Specialist Hospital & Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2012.01.010"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2006.06.014"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/11206721221127769"},{"key":"e_1_3_3_5_2","first-page":"8","article-title":"Botulinum toxin chemodenervation of the inferior oblique muscle for chronic and acute IV nerve palsies: results in 15 cases","volume":"13","author":"Carden SM","year":"1998","unstructured":"Carden SM. Botulinum toxin chemodenervation of the inferior oblique muscle for chronic and acute IV nerve palsies: results in 15 cases. Binocul Vis Strabismus Q 1998; 13: 8.","journal-title":"Binocul Vis Strabismus Q"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3928\/0191-3913-19800101-06"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.4321\/s0365-66912004000300005"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.4103\/2008-322X.170350"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.07.003"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/11206721251367813"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.4103\/sja.SJA_543_18"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.21037\/qims-22-467"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273972.2025.2452623"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006499.pub4"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721251414695","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11206721251414695","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721251414695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:01:37Z","timestamp":1781920897000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11206721251414695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/11206721251414695"],"URL":"https:\/\/doi.org\/10.1177\/11206721251414695","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]}}}